Kannalife Sciences, Inc. is a drug discovery company with globally patented anti-inflammatory technology. Our lead compound KLS-13019, is a first-in-class, novel IND enabled synthetic cannabinoid that has been validated through IND enabling studies to prevent and reverse chemotherapy induced peripheral neuropathy (CIPN). Peripheral neuropathy is a completely different class of pain, which is not the same as analgesic pain and mechanistically different. In addition to our drug’s ability to reverse peripheral neuropathy, animal studies have shown KLS-13019’s ability to reduce morphine reward seeking behavior.